ABVC BioPharma Inc (ABVC)

[TheFinalCD]

$ABVC 2.01 DIP


FOR THE DIPCHITS

[subslover]

As of November 9, 2023, there were 7,231,940 shares of common stock, par value per share $0.001, issued and outstanding.

[subslover]

ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees
FREMONT, CA , Jan. 03, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) and its subsidiary BioLite, Inc. ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that the Company and its subsidiary received an aggregate of 46 million shares from AiBtl BioPharma Inc. ("AiBtl"), as its first milestone payment under a global licensing agreement. The agreement between the Company and AiBtl placed a value of $460 ($10 per share) on such payment. AiBtl is a private company, and the share value is based on the terms of the agreement between the parties and the valuation report done by an independent third party.

The Company entered into a definitive global licensing agreement with AiBtl on November 12, 2023, for the Company's CNS drugs with the indications of MDD (Major Depressive Disorder) and ADHD (Attention Deficit Hyperactivity Disorder). According to the terms of the agreement, AiBtl delivered 46M shares to the Company as the first milestone payment. The Company expects AiBtl to achieve the further milestones under the agreement, upon which the Company may receive the remaining licensing fees of up to $7M cash and 5% royalties of net sales, up to $200M.

"I am pleased with the progress of ABVC and AiBtl's collaborative work, which reflects ABVC's strength to grow and increase cash flow," said Uttam Patil, Ph.D., Chief Executive Officer of ABVC. He continued, "After this licensing payment, AiBtl becomes a subsidiary of ABVC, which holds 57% of the consolidated shares of AiBtl; accordingly, AiBtl is now also considered a related party.
“We believe this milestone payment marks the beginning of ABVC's revenue generation through licensing deals and opens new avenues that could potentially increase ABVC's revenue. AiBtl will help ABVC conduct international business development for the MDD and ADHD markets and bridge the partnership with international pharmaceutical companies."

"Completing out-licensing for the licensed products is our priority to strengthen our collaboration with ABVC," said AiBtl's Chief Executive Officer Russman Jaimes. He further commented, "AiBtl is a US company registered in Delaware. We are working on progressive joint ventures in Asia to expand the healthcare business and are poised to strengthen it. With ABVC's strong pipeline of products, we believe AiBtl has a strong future."

Management believes the Company's pipeline of products has excellent market potential. As per the Future Market Insights report, the MDD market was valued at $11.51 billion in 2022 and is expected to reach $14.96 billion by 2032 with a CAGR of 2.8% over the forecast period[1]. According to the Polaris market research report, the global ADHD treatment market was valued at $15.23 billion in 2022 and is expected to grow at a CAGR of 7.3% over the forecast period between 2023-2032.[2] Straits Research reports that the global botanical drug market size was valued at $163 million in 2021 and is expected to be valued at $3.2 billion; the market is expected to grow at a CAGR of 39% during the forecast period (2022–2030).[3]

About ABVC BioPharma & Its Industry
ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development. For its drug products, the Company utilizes in-licensed technology from its network of world-renowned research institutions to conduct proof-of-concept trials through Phase II of clinical development. The Company's network of research institutions includes Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus®, the Company intends to conduct global clinical trials for PMA (pre-Market Approval).

Forward-Looking Statements
This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential," or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified, and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. None of the outcomes expressed herein are guaranteed. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to proceed to the next level of the clinical trials or to market our product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy any of the Company's securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of the Company's securities in any state or jurisdiction in which such offer, solicitation or sale wo

[TheFinalCD]

https://finviz.com/quote.ashx?t=ABVC&p=d

Full Ratchet
https://dilutiontracker.com/app/search/ABVC

November 2023 Note Warrants
Not Registered

Remaining Warrants Outstanding
1,000,000
Exercise Price
$2.00

[kbaz]

KABOOM!!!! Super Launching Going on here!!!!!

[kbaz]

Slow March to Glory!!!! '24 gonna be a Fine Year!!!!!

[Biorat]

The Promising Future of Vitargus: A New Chapter in Retinal Tamponade?

The management of retinal detachments (RDs) has long relied on retinal tamponades, commonly gas bubbles or silicone oil. While effective, these options come with limitations and potential complications. Enter Vitargus, a novel injectable polymer under development, presenting a potential paradigm shift in retinal tamponade. Here's how Vitargus could become a game-changer:

Addressing the Drawbacks of Current Tamponades:

Long-term complications: Gas bubbles require repeated injections, posing risks like cataract formation and elevated intraocular pressure (IOP). Silicone oil often necessitates additional surgery for removal, carrying infection and vision-threatening risks. Vitargus, being biodegradable and potentially requiring fewer injections, could mitigate these long-term concerns.

Visual distortions: Gas bubbles and silicone oil can cause visual distortions due to their refractive properties. Vitargus, with its similar refractive index to vitreous humor, may offer improved visual clarity compared to traditional tamponades.

Discomfort and limitations: Gas bubbles can induce floaters and discomfort, while silicone oil limits certain activities like flying. Vitargus, by potentially causing minimal visual disturbances and allowing for a wider range of activities, could improve patient quality of life.

Unlocking Potential Advantages of Vitargus:

Targeted and sustained tamponade: Vitargus, designed to gel within the vitreous cavity, could provide targeted and sustained tamponade, potentially leading to improved anatomical reattachment and faster visual recovery.

Biodegradability and biocompatibility: Biodegradable Vitargus eliminates the need for removal surgery, simplifying the treatment process and minimizing potential complications. Its biocompatibility also reduces the risk of inflammatory reactions compared to silicone oil.

Adjustable tamponade pressure: Vitargus formulations may allow for tailoring the tamponade pressure based on individual needs and RD severity, potentially optimizing outcomes.

The Road Ahead:

While preliminary investigations show promising results, further clinical trials are crucial to definitively establish Vitargus's efficacy and safety compared to established tamponades. Nevertheless, its potential to address the limitations of current options and offer several unique advantages positions Vitargus as a noteworthy innovation in the field of retinal detachment management.

[1hot toddy]

we also got $8 in cash plus stock on last deal $$$$$$$$$$$

[Biorat]

Why Vitargus® Could Push ABVC Shares Beyond $35: A Factual Analysis
While predicting the future of any stock is inherently uncertain, here are some factual reasons why Vitargus®, ABVC's breakthrough retinal surgery implant, has the potential to drive its share price above $35:

1. Market Size and Growth:

The global market for retinal surgery devices is expected to reach $4.3 billion by 2029, driven by an aging population and rising demand for minimally invasive procedures. (Source: iHealthcare Analyst, Inc.)
Vitargus® targets a specific segment of this market with its unique biodegradable implant design, potentially capturing a significant share.
2. Game-Changing Technology and Potential Advantages:

Vitargus® eliminates the need for a second surgery to remove the implant, unlike traditional methods, potentially leading to faster recovery times and improved patient comfort.
Early studies suggest it could also eliminate the need for post-operative face-down positioning, further improving patient experience.
These advantages, if proven in Phase II trials, could make Vitargus® a highly sought-after product and differentiate it from existing options.
3. Positive Analyst Sentiment and Upcoming Data:

Several analysts have expressed optimism about Vitargus® and its potential impact on ABVC's future.
The upcoming Phase II trial data release in Q4 2023 is a critical catalyst that could significantly impact the stock price. Positive results could trigger a surge in investor confidence and lead to upward revaluations.
4. Potential Partnerships and Distribution Agreements:

Major pharmaceutical companies are reportedly interested in partnering with ABVC for Vitargus® distribution and/or manufacturing, potentially injecting significant revenue into the company.
Early distribution agreements in Asia and Australia could further boost ABVC's financials and attract further investor interest.
5. Valuation Potential:

Some analysts believe that ABVC's current valuation does not fully reflect the potential of Vitargus® and its future revenue streams.
A successful commercialization of Vitargus® could significantly increase ABVC's earnings and justify a higher share price, potentially exceeding $35.
Important Caveats:

The success of Vitargus® is not guaranteed, and the market reaction to the Phase II data remains uncertain.
The overall market conditions and investor sentiment can also impact ABVC's share price.
This information is for educational purposes only and should not be considered financial advice.
Conclusion:

While pushing past $35 is not a guaranteed outcome, Vitargus® presents a compelling case for potential future growth of ABVC. Its innovative technology, market potential, and upcoming data release make it a story worth watching closely for investors interested in healthcare and disruptive medical devices.

Remember, always conduct your own research and consult with a qualified financial advisor before making any investment decisions.

[1hot toddy]

CO GOT MORE IN CASH AND STOCK FROM LAST DEAL THAN OUR WHOLE MARKET CAP $$ OVER 2/1

[crudeoil24]

ABVC hit 1.47 earlier in session. We should hear more patent news from company later this month.

[timetomakemoney]

If ABVC can't hold support at 1.20 then 1.05 is the next level. GLA my IMO.

[timetomakemoney]

Hit 1.31. If can't hold 1.30 next support level 1.20

[timetomakemoney]

ABVC next support 1.30. PPS is being walked down on low volume.

[Biorat]

1) Electronic Communication Networks ARCA & NSDQ do not communicate by design.This often creates a cross locked situation where the bid and ask are temporarily the same - in extended hours trading sessions it's easier to spot. What that means for example is that company XYZ can have a bid price of $5.01 routed through ARCA and a $5.01 ask price routed through NASDAQ creating an equal bid and ask that won't execute. If the bid on ARCA is increased to $5.02 a lightning fast computer takes the trade. The result is free money multiplied by every share on the bid being shaved .009 cents while making themselves (market makers) look good to the bidding retail customer. The bidder is told he received a price adjustment in his favor of .001 per share or a $5.019 fill. On the other side the ask never new a better bid existed. In effect the market maker took .009 from the bidder because a better ask existed. lf the trade was 10,000 shares in size and multiplied by .009, that's a $90 profit on one trade without risk to the market maker. How do I know about this? Once, I was on both sides of the trade and received the adjustment of .001 per share and nothing on the other side. Multiply this by every trade situation like this going on in every stock every day in the market and you get the picture.

2) On stocks over $1 in share price, notice the fractional trades executing on level II. Retail traders\investors can't place bids or asks in fractional trade format for stocks trading over $1.00. Something like the situation in number #1 above has taken place every time you see a fractional trade in these stocks. There are more Electronic Communication Networks than just ARCA and NASDAQ used in the example in #1.

3) You will notice ADF trades on level II as having been executed often - this is a relatively recent scam as if retail wasn't already at a disadvantage. ADF stands for alternative display facility in effect a "dark pool" that can't be seen by retail investors. Since retail can't see these bids or asks on level II this allows the market makes to circumvent the rules that govern the best bid and ask hierarchy for execution always placing them at the front of the trading line when their lightning fast computers see a favorable trade.

4) Day traders often buy high at the ask to get the large quantity of shares required to overcome a commission on a small move. A buy at the ask is fast and will not tip the other traders off as to the number of shares taken till after the fact. If not done fast at the ask the price would move against the traders own effort before they have a large position. This means the trader at least temporarily holds shares higher than the current best bid creating an immediate loss and a bigger loss if the trade turns out to be a bust. A wide bid ask spread is often maintained by the market makers when they see high volume and volatility together. If a trader jumps in between the spread with the intent to close the spread a lightning fast machine can take that effort and make a profitable trade for the market makers.This is done instantly inside the ADF and other dark pools that exist between the spread and hidden from retail. This also serves to maintain the desired spread the market makers and not retail dictate.

5) Shorting: Brokers and market makers work in conjunction with one another controlling who can short and who pays a fee to borrow shares, if they allow retail to borrow shares at all. Even legitimate shorting serves to dilute the value of the shares that exist in retail hands. How you may ask? Example: 10 shares exist in stock XYZ and are in your account, then the broker you trust loans them out to someone. That someone (often a market maker) sells your own shares to the favorable bid and you lose the favorable bid pressure. Now the person sold to owns 10 shares and you hold 10 shares or believe you hold 10 shares.That in effect creates 20 shares out of 10. Extend the example to higher share counts and again you get the picture. That's not even going into the naked shorting where shares are printed before seeing if any exist to borrow. The markets trade just fine with no shorting at all and have at times. Shorting is the biggest fraud perpetrated on the investing public and a destroyer of any company trying to raise capital while shorts are attacking their reputation. Market makers should not be allowed to be in the business of deciding what companies should be taken down just because they may be a "bad investment". Real people are already invested taking away the argument about helping the public. What market makers are doing is helping themselves to profit through shorting an easy target. Companies are often weak because the rampant shorting destroyed their ability to raise capital in the first place. If a company is such a "bad risk" that retail must be protected from higher share prices why are these companies on the exchange in the first place? A higher share price does not hurt investors entry any more than a low share price. An investors wallet and not the share price dictates the share number held. A $2000 investment is still a $2000 investment regardless of share price you still lose $2000 if the stock goes to zero. Free markets and not market makers should ultimately decide what company survives or not. Don't expect to see that because it's not in their best interest where helping themselves to your money is.

6) Shorts have the advantage because they can show large sells (ask price) with no intention of having them executed to "spook" the price down.The short advantage is maintained since longs would like in at the lowest price possible. This greed prevents the longs from "hitting the ask" and punishing the shorts who attempt the manipulation. If the longs were hitting the ask constantly the shorts would become overextended. Longs are at risk when playing the same game (showing large bids) because sellers exist more readily and are scared into selling by the shorts who are probably using those sellers (longs) own shares against them.. Shorts, as explained have future longs as allies since future longs help deceive the current longs to gain a more favorable entry price.

Don't forget any type of shorting is diluting the share count\value and can double the sellers... when shorts sell they do it in an effort to drive down the stock price. When shorts buy to cover they can use extended hours, lunch hour or any time that will not spook the price higher and they can hide their buy sizes. Advantage shorts.

7) Market makers have cover stories explaining why a stock is going down and preventing their manipulation from being discovered as the real cause of price decline. Example blame an earnings report even if good. Sell the news is a saying and they will use it! If the news is bad, use that excuse for sure. Not bad enough news? Just say that investors didn't like something about it. If no news exists blame the overall market conditions or an election, war, event in the news that could effect stocks etc.... the list is endless. It couldn't be the large sell orders that shorts show to "spook" the bids right on the opening bell to choke off the buying volume right? Here's a kicker if a retail bidder (long) shows an order in attempt to move the price higher the market makers can choose not to display that bid because they will say it's and attempt at manipulation. As if the shorts are not engaged in manipulation... lol.

With the siphoning of money from retail market participants happening will long term investors get rewarded for being long term investors? Maybe, however, far less than should be the case since the money is now in the market makers hands vs retail where the money would continue to be invested. Make no mistake retail is being cheated every day, long and short term investors alike. Even stocks in 401K's lose value when the market makers short stocks. No matter the investment time horizon that equals bad news for retail investors. If you're one of the few investors who make good choices long term and comes out ahead, you're not as far ahead as you could have been without the corruption.

The solution? Take this information and demand that politicians clean up the markets. The best place to start is getting rid of all forms shorting. The market does work without shorting just fine! It just doesn't work as well for the market makers who will claim it's needed and other big players they support will agree with them. Who should the markets be designed to help retail investors and the companies trying to create and maintain a business or large players with unfair advantage who feed off those two groups?

[timetomakemoney]

Looking at the Chart 1.78 needed to hold. I believe the next support level is near 1.5. Unless the company releases news. JMO

[1hot toddy]

wait till 10q comes out and shows they got more cash and stock than market cap $$$$$$$

[timetomakemoney]

Borrowing fees to short ABVC
is till over 200 percent..

[1hot toddy]

we got more cash in last deal than our whole market cap plus ton of stock $$$$$$$$
co very undervalued

[crudeoil24]

Back in here. ABVC is a fabulous upside opportunity!

[timetomakemoney]

Check this out:
https://www.iborrowdesk.com/report/abvc
216.3 % 100 2023-11-21 12:15:03

Fricken huge 216.3 precent fees to borrow shares of ABVC and only 100 shares are available!

[1hot toddy]

there running out of shares only 4 mil shares in float $$$$$$$$

[MJAM2020]

Yes how can it keep seeing this amount of volume and not make a significant step up that holds.

Imho

[stock1ace1]

$2.22 what a run today

[timetomakemoney]

Upgrades coming soon.

[timetomakemoney]

Need to hold 1.78.

[timetomakemoney]

Great Volume over 13 million before NOON!

[timetomakemoney]

yes, Great News

[kbaz]

Over 2 million in Volume Pre Market!?!?! This is a ROCKET RUMBLE on the STARSHIP SUPERNOVA......

[IVANj]

Let’s gooo

[kbaz]

Movin' on up!!!!

[Awl416]

ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion Market

[timetomakemoney]

The PPS is back filling nicely. Needs to break 1.80 and then it will breakout.

[1hot toddy]

big buys $$ 18000 share buy $1.70 stock sooooo undervalued UP UP AND AWAY $$$$$$$$$

[1hot toddy]

we got a market cap of now 7 mil and we got 9 mil in cash plus alot of stock. two deals ago. now we got another licensing agreement. thats 2 in month. we got more cash and equity in 2nd agreement. stock soooooooooo undervalued. next 10q going to rock. im buying even more for big run up.

[kbaz]

ABVC has a History of MASSIVE SPIKES couple with Big Pull Backs. We've only been feeling Tremors of a breakout to this point. Could take a Month.

[kbaz]

Anything Can Happen when POTENTIAL could be massive.

[timetomakemoney]

I've been buying in the low 1.00 range. Will add more if PPS dips back down.

[kbaz]

Not to be Smartass, However may want to really do some DD here. Some Pretty Exciting News considering the 09/32/23 Actual Market Cap.

Im sure like others that many insiders have/are receiving incentive Equity since this report....

[timetomakemoney]

PPS needs to break 1.80 resistance and then we are off to the races.

[1hot toddy]

4 mil $$$$$$$$$$$

[1hot toddy]

2-10000 share buys $$$$$$$$$$

[timetomakemoney]

What is the float and is OS 6 million? Thank you

[1hot toddy]

we only have market cap of 6 mil and we got 9 mil in cash and alot of stock on deal 3 wks ago. now add this deal in and i can see us moving towards our high

[kbaz]

Have no Idea how this goes over the upcoming funky breakups in Normal Trading days. Looking for FIREWORKS.........

[stock1ace1]

$1.57 watch for a/h run

[stock1ace1]

$1.50

[stock1ace1]

$1.44 breakout watch !

[stock1ace1]

17 mill vol 3 mill o/s huge contract news float lock up ?

[stock1ace1]

Huge news 3 mill o/s tiny float ->

ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200M